Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Candel Therapeutics (CADL) just unveiled an update.
Candel Therapeutics, Inc. has revealed promising interim results from a phase 2 trial of CAN-2409 for treating non-metastatic pancreatic cancer, showing notably improved survival rates compared to the control group. Patients treated with CAN-2409 experienced a median overall survival of nearly 29 months, a stark contrast to the 12.5 months in the control group. Moreover, the treatment induced a significant immune response and maintained a favorable safety profile, bolstering hope for its potential as a viable therapeutic option.
See more data about CADL stock on TipRanks’ Stock Analysis page.
